Daraxonrasib Is Changing the Standard of Care in Second-Line Metastatic Pancreatic Cancer

Metastatic pancreatic ductal adenocarcinoma (mPDAC) remains one of the most lethal malignancies in oncology, and the second-line treatment landscape has long been defined by modest incremental gains. Available second-line therapies offer median progression-free survival (PFS) of just 3 to 4 months and median overall survival (OS) of 6 to 7 months—outcomes that underscore the urgent need for more effective approaches.

Results from the RASolute 302 phase 3 trial (NCT06625320), presented at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago, represent a potential paradigm shift: daraxonrasib, a first-in-class oral RAS inhibitor, demonstrated statistically significant and clinically meaningful improvements in both OS and PFS vs chemotherapy, with investigators characterizing the results as unprecedented in this setting.

The Biological Rationale

Pancreatic cancer is among the most RAS-driven malignancies known. Despite this well-characterized driver, RAS has historically been considered undruggable because of its smooth surface, which offers few obvious binding sites for small molecules.

“More than 90% of pancreatic cancers harbor an activating RAS mutation, most commonly KRAS G12D, G12V, and G12R. Excessive RAS‑on signaling drives tumor growth in RAS‑mutant and the majority of RAS wild‑type pancreatic cancers. No RAS‑targeted therapies are currently approved for use in patients with pancreatic cancer.”¹

Daraxonrasib represents a new class of RAS inhibition: an oral, multiselective tri-complex inhibitor that targets the active, GTP-bound state of mutant RAS, distinguishing it from earlier covalent inhibitors that were limited to specific mutations, such as KRAS G12C.¹

“Daraxonrasib is a RAS‑on multiselective tri‑complex inhibitor of GTP‑bound RAS, including wild‑type RAS and mutant RAS at codons G12, G13, and Q61,” explained Brian M. Wolpin, MD, MPH, Hale Chair in Pancreatic Cancer at Dana-Farber Cancer Institute and professor of medicine at Harvard Medical School.¹

Critically, daraxonrasib also demonstrates activity against wild-type RAS, broadening its potential applicability across the PDAC population regardless of specific mutation subtype.

RASolute 302 is a global, randomized, open-label phase 3 study enrolling patients with second-line mPDAC and an ECOG performance status of 0 to 1. Five hundred patients were randomly assigned 1:1 to receive daraxonrasib 300 mg orally once daily or the investigator’s choice of standard-of-care cytotoxic chemotherapy. The trial had dual primary end points: OS and PFS, assessed by blinded independent central review (BICR) in the population with the RAS G12 mutation.

Key secondary end points included OS and PFS in the overall population and objective response rate by BICR in both the RAS G12 and overall populations. Baseline characteristics were well balanced between arms, and the median follow-up at the February 10, 2026, data cutoff was 8.5 months.²

Daraxonrasib Met All Primary and Secondary End Points

Daraxonrasib demonstrated statistically significant, clinically meaningful improvements in both OS and PFS vs chemotherapy in the RAS G12 mutant population and in the overall population. The breadth of benefit across both populations is particularly notable, suggesting that daraxonrasib’s activity extends beyond tumors harboring specific G12 mutations—consistent with its mechanism of action against both mutant and wild-type RAS.^1,2

“Similar to overall survival, RASolute 302 demonstrated a statistically significant improvement in progression‑free survival by blinded independent central review, favoring daraxonrasib compared [with] chemotherapy in both the RAS G12 population and the overall population, with hazard ratios of 0.45 and 0.49, respectively,” said Wolpin.¹

The median daraxonrasib dose intensity was 93.1%, with a mean of 84.7%, indicating that most patients maintained near-full dosing throughout the treatment period—a meaningful indicator of tolerability in a patient population that often faces a treatment burden.^1,2

Daraxonrasib Safety Compared Favorably to Chemotherapy

Grade 3 or higher treatment-related adverse events (TRAEs) occurred in 43.6% of patients receiving daraxonrasib vs 57.5% receiving chemotherapy. The most common grade 3 or higher TRAEs with daraxonrasib were rash (13.7%) and stomatitis (12.0%)—manageable, on-target effects consistent with RAS pathway inhibition. In the chemotherapy arm, the most common grade 3 or higher TRAEs were neutrophil decrease (18.2%) and anemia (16.4%), reflecting the well-known myelosuppressive burden of cytotoxic therapy in this population.^1,2

Treatment-related serious adverse events occurred in 10.8% of patients on daraxonrasib vs 18.7% on chemotherapy. Perhaps most strikingly, discontinuation due to TRAEs was just 1.2% with daraxonrasib compared to 11.2% with chemotherapy—a nearly 10-fold difference that highlights the drug’s tolerability and its potential to keep patients on therapy longer. No new safety signals were identified.^1,2

“The time to symptom deterioration for both pain and global health status/quality of life was prolonged for patients who received daraxonrasib compared [with] patients who received chemotherapy, with hazard ratios of 0.51 and 0.6, respectively,” explained Wolpin.¹

A Potential New Standard of Care

RASolute 302 establishes daraxonrasib as a compelling new standard of care for second-line mPDAC, a disease in which meaningful progress has been elusive for decades. The survival improvements observed here, characterized by the investigators as unprecedented in this setting, combined with a tolerability profile that meaningfully outperforms that of chemotherapy, position daraxonrasib as a practice-changing advance. The drug’s activity across both RAS G12 mutant and overall populations also raises important questions about the role of RAS wild-type signaling in PDAC and whether broad RAS inhibition may ultimately prove more effective than mutation-selective approaches.

For patients facing a second-line pancreatic cancer diagnosis—historically one of the most difficult situations in oncology—these results offer a meaningful new reason for optimism.

REFERENCES

1. Small E, Chein J, Dickson MA, et al. Plenary session. Presented at: 2026 American Society of Clinical Oncology Annual Meeting; May 29-June 2, 2026; Chicago, IL.

2. Wolpin BM, Wainberg ZA, Hendifar A, et al. Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC): primary and final analysis from the phase 3 RASolute 302 study. Presented at: 2026 American Society of Clinical Oncology Annual Meeting; May 29-June 2, 2026; Chicago, IL. Abstract LBA5.